# Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

> **NCT02513498** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Ixazomib Citrate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02513498
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-08
- **Primary completion:** 2018-01-05
- **Final completion:** 2018-06-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02513498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02513498, "Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02513498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*